Overnight urine growth hormone, cortisol and adenosine 3′ 5′ cyclic monophosphate excretion in children with chronic asthma treated with inhaled beclomethasone dipropionate  by Zeitlin, S. et al.
Respiratory Medicine (1993) 87,445~448 
Overnight urine growth hormone, cortisol and adenosine 
3’ 5’ cyclic monophosphate excretion in children with 
chronic asthma treated with inhaled beclomethasone 
dipropionate 
S. ZEITLIN*$, P. Woo@‘, A. EvANst AND M. RADFORD* 
*Department of Child Health and the TRegional Endocrinology Unit, Southampton General Hospital, 
Southampton SO9 4XY, U.K. 
Overnight urine samples were obtained from 34 asthmatic children, 24 of whom were receiving inhaled 
beclomethasone dipropionate (BDP), and 30 controls. The urine volume of the children receiving inhaled 
steroids was significantly greater than that of the other asthmatic children and of the controls (P<O.O5). 
Urine growth hormone was within the normal range for all of the subjects and there was no demonstrable 
relationship between urine growth hormone and height or height standard deviation score. Urine steroid output 
was significantly reduced in the BDP receiving group when the results were expressed in U 1-l but there was 
no difference between the groups when the results were expressed per specimen. Urine adenosine 3’ 5’ cyclic 
monophosphate (CAMP) results were similar for all groups. We conclude that use of BDP increases overnight 
urine volume but, in our study, does not appear to influence the output of urine cortisol. Urine free cortisol 
measurements may not be a very sensitive tool for the detection of small changes in endogenous steroid 
production. The use of BDP does not adversely affect the output of urine growth hormone. 
Introduction 
Inhaled glucocorticosteroids are one of the most 
useful and controversial medications used in the 
management of childhood asthma. The extent to 
which topical steroids are systemically absorbed is of 
primary concern. 
Systemic adsorption may result in hypothalamic- 
pituitary-adrenal suppression thereby causing reduc- 
tion or alteration in endogenous steroid production or 
by adversely affecting growth (I), by some alternative 
mechanism. 
Much conflicting information has been published 
about the relative safety of inhaled steroids. This 
reflects the diverse populations selected and the 
methods used to assess them. 
Children who suffer from chronic asthma may be 
shorter than normal. Causes of poor height growth 
other than glucocorticosteroids may include stress 
caused by hypoxaemia, especially during sleep, and 
abnormal production or sensititivity to endogenously 
produced growth hormone (2). Reduced energy intake 
and increased energy expenditure associated with the 
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increased work of breathing during episodes of acute 
respiratory distress may also influence growth. 
The aim of this study was to define a group of 
children with comparable severity of asthma and to 
look at the relationships between height growth, 
inhaled steroid usage and endogenous steroid 
production. We also studied their overnight growth 
hormone production and output of adenosine 3’ 5’ 
cyclic monophosphate (CAMP), an index of short term 
stress. 
Methods 
Thirty-four children (nine girls and 2.5 boys) 
suffering from chronic perennial asthma participated 
in the study. Twenty-four of the children were taking 
regular inhaled steroid therapy. Thirty healthy school 
children (17 girls and 13 boys) were recruited as 
controls. Local ethical committee approval was 
obtained for the study and informed consent was given 
by the participants’ parents. 
The asthmatic children were recruited from 
paediatric outpatient clinics at Southampton General 
Hospital. 
Each asthmatic child kept a standard asthma diary 
for 28 days. They recorded the best of three attempts at 
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peak expiratory flow rate (PEFR) on rising in the 
morning before using any medication and again at 
night before going to bed. The Wright’s mini-flow 
meter was used to record all readings. All medication 
taken was recorded. Twenty-four of the children 
were receiving regular inhaled glucocorticosteroid 
therapy. All of these patients had been treated with 
beclomethasone diproprionate for a minimum of 3 
months. By means of the diaries the number of days 
on which the PEFR was less than 75 % of the predicted 
value and the number of days when the diurnal 
variation was greater than 25% of the predicted value 
was calculated. All of the asthmatic children took 
inhaled bronchodilators. None of them took oral 
theophylline. 
The children were weighed, and measured using a 
stadiometer. Their height standard deviation score 
and their surface areas were calculated (10). 
The children were all continent of urine at night. 
When they had completed the asthma diaries they were 
asked to collect a timed overnight urine specimen. 
The urinary creatinine concentration of each specimen 
was determined using the Jaffe alkaline pyruvate 
technique. Urinary free cortisol was measured by 
specific radioimmunoassay (11) with a detection limit 
of 8 nmol 1-l and a between batch precicion ranging 
from 12.6 to 15.2% for the low, median and high 
controls. CAMP was analysed with the bovine adrenal 
protein kinase competitive binding method (12); 
between batch precicion was 13.2 and 13.9% for low, 
median and high controls. The overnight output of 
urinary human growth hormone was measured using 
an assay described by Evans et al. (13). The method 
will detect 0.5,uUl-’ urine with between batch 
precicion of 5.5-16.9% for low, median and high 
controls. 
Results 
The children suffering from asthma had a mean 
age of 8.55 years (6.69-10.76). The mean age of the 
control children was 9.00 (7.52-10.88) years. All of 
the children had a puberty rating of 1 on a physical 
examination (14). 
The mean dose of beclomethasone diproprionate 
was 341 pgd-’ (range=200-1200pg). 
The number of days on which the PEF was less than 
75% of the predicted peak flow was not significantly 
different for the children receiving steroids compared 
with the asthmatic children not taking steroids. 
Similarly no significant difference was found between 
the groups for the number of days when the diurnal 
variation was more than 25% of the predicted peak 
flow. This suggests that the severity of disease was 
comparable for the two groups of asthmatic children 
during the study period. The records of inhaled 
a-agonist usage were not accurate, additional doses 
taken during the day were infrequently recorded. The 
results were not analysed. 
Urine volume was measured for each patient. The 
mean volume for the control children was 220 f 106 ml 
(mean &SD) per overnight collection. The volume 
for the asthmatic children who were receiving BDP 
was 300 + 120 ml and for those children with asthma 
but not on BDP the volume was 180 f 56 ml. Non- 
parametric analysis using the Mann-Whitney U-test 
revealed a significant difference between those 
receiving BDP and the controls (P~0.05) and 
asthmatics not on BDP (P~0.05). This result has 
an important influence on the interpretation of the 
subsequent data. 
When urine creatinine expressed as mmol 1-l was 
compared there was a highly significant difference 
between those asthmatics on BDP and those who were 
not (P-C 0.01). There was no significant difference 
between the lean body mass of these two groups. 
However, when the difference in urine volume was 
taken into account and the results were expressed as an 
amount per specimen there was no difference between 
the groups. 
The urinary cortisol concentration was also 
expressed both as an amount per litre and per 
specimen. Urine cortisol expressed as an amount per 
litre showed a significant difference between those 
asthmatic subjects receiving BDP and those who 
were not (P-=0.01). When the values for children 
receiving BDP were compared with the controls again 
the difference was marked (PeO.01). However when 
the amounts of urinary cortisol per overnight speci- 
men were compared it was not possible to show any 
difference between the groups. 
We went on to explore the relationship between 
the concentration of urinary free cortisol both per 
specimen, and per litre, with the dose of BDP taken 
in 24 h. We were unable to show any significant 
correlation between the dose of BDP administered 
either in absolute terms or as an amount per square 
metre of surface area, or per kilogram of lean body 
mass, or per kilogram of body weight. 
Urinary CAMP was measured in the urine samples. 
No significant difference was noted when the samples 
from asthmatic children were compared with those 
from the controls if the results were expressed as a 
concentration per litre. There was a significant 
difference when the results from asthmatics taking 
BDP was compared with those who were not (P< 0.5) 
but this disappeared when the amount of CAMP per 
specimen was compared. 
Chronic asthma and inhaled BDP 447 
Analysis of urinary growth hormone concentration 
per specimen showed no difference between the two 
groups of asthmatic children. All of the results fell 
within the normal range established for prepubertal 
children for this laboratory (15). There was no 
correlation between height standard deviation scores 
and the overnight urine HGH concentration. 
Discussion 
Inhaled steroids have proved to be a useful adjunct 
in the management of childhood asthma. Whilst their 
therapeutic value is proven significant doubts still exist 
about the extent to which they are systemically 
absorbed. 
It has been shown that inhaled beclomethasone 
diproprionate is to some extent absorbed. Serial serum 
sampling has been used to demonstrate that the overall 
production of endogenous steroid is diminished (16). 
The clinical significance of these observations is less 
certain. 
Asthma is associated with an altered pattern of 
linear growth. Recently a distinctive pattern has been 
described. Children appear to gradually fall away 
from their predicted height centile as they approach 
puberty. The onset of sexual maturation is delayed 
hence the duration of growth is prolonged and for the 
most part they ultimately attain their predicted adult 
height. The cause of this pattern of growth has been the 
subject of much speculation (17,18). 
The children that we studied were felt to be suffering 
from similar severity of asthma symptoms at the time 
of their entry into the trial. The use of anti-asthma 
medications, in particular anti-inflammatory drugs 
will inevitably influence the course of the underlying 
disease so that whilst symptoms appeared to be of 
comparable severity at the time of the study it would be 
highly speculative to comment upon the inherent 
severity of the disease itself. This fact may contribute 
to the discrepancy in the height of the two groups of 
asthmatics. Since there are no reliable clinical indices 
of the inherent severity of asthma, cross sectional 
studies of growth are never easy to interpret. 
Abnormal production of human growth hormone 
has been postulated as the cause of growth delay in 
asthma. Growth hormone stimulation tests have failed 
to yield abnormal results (6). In this study we chose to 
measure unstimulated growth hormone production. 
We showed no demonstrable relationship between the 
output of hormone and linear growth or the use of 
inhaled steroids. Reduced sensitivity to or production 
of growth cofactors still remain to be investigated. 
Poorly controlled asthma is associated with an 
increase in nocturnal symptoms. Episodic drops in 
oxygen saturation as well as frequent disturbance of 
sleep may give rise to short term stress (5). Cyclic AMP 
has been used as an index of stress in patients who have 
suffered thermal burns (19). It may be measured in 
urine specimens. The output of CAMP is unaffected 
by diet or by the use of theophyllines but can be 
increased by /?-agonists (20,21). However, when 
P-agonists are used regularly the rise in output of 
CAMP is considerably less marked (22). We were 
unable to show any difference in the production of 
CAMP between the asthmatic and control subjects. 
This suggests that our asthmatic children were, as their 
diaries suggested, reasonably well controlled for the 
duration of the study. 
Finally, we attempted to re-explore the relationship 
between the use of inhaled steroids, suppression of 
the hypophyseal-pituitary-adrenal axis, and growth 
retardation. This subject has been investigated by many 
groups in the last 20 yr with results often at variance 
from one another. Previous studies can be roughly 
divided into those which use early morning plasma 
cortisol level with or without short term tetracosactrin 
tests, and those that use the output of urine steroids. 
Interpretation of these studies is complicated by 
variations in the inhaled steroid used and whether or 
not the subjects were receiving the medication for the 
first time and the use of oral steroids. Studies using the 
output of urinary steroids more consistently appear to 
show suppression by inhaled steroids (3,24,25). 
In this study we chose to use an overnight urine 
collection. The indefinite period of this collection is a 
disadvantage but since the duration of sleep, and hence 
circadian rhythm is subject to individual variation it 
was felt that this period of time reflects the output of 
hormones that are influenced by diurnal variations. 
We showed that the children taking inhaled BDP 
had significantly greater overnight urine volumes than 
either the control children or those asthmatics not 
taking steroids. 
We failed to demonstrate any difference in the 
production of urinary cortisol between asthmatic 
subjects receiving BDP and either those children 
taking only inhaled salbutamol or the healthy con- 
trols. If the results are expressed as cortisol: creatinine 
ratios or as concentrations of cortisols per litre then 
it is possible to show differences. However, it should 
be borne in mind when interpreting these results an 
optimal sample size of more than 200 subjects would 
ideally be required to demonstrate differences in the 
cortisol:creatinine ratio. Few existing studies have 
been performed on this scale. 
As with all glucocorticosteroids BDP has a potential 
mineralocorticoid affect. Since there was no evidence 
that there was a significant difference in the severity of 
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symptoms between the two groups it is likely that 
changes in the urine output of those children taking 
BDP were a consequence of the systemic effects of 
inhaled steroids. 
Urinary free cortisol measurement may not be a 
sufficiently sensitive test to reveal small differences 
in net cortisol production. Indeed it was designed as a 
test of states of excess rather than deficiency (23). 
Glucocorticosteroids also have a permissive action 
directly on the kidneys affecting the control of diuresis 
and concentration. 
There is no doubt that some children who suffer 
from asthma fail to grow at the anticipated rate during 
childhood. The causes of this observation remain 
obscure and it seems likely that no one single factor can 
be incriminated. 
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